Cerecor Acquires Rights to Merck's Depression Candidate
By Catherine Shaffer
Monday, April 22, 2013
Cerecor Inc. acquired rights to an NMDA (N-methyl-d-aspartate) antagonist for development in the area of depression from Merck and Co. Inc. The drug, MK-0657, was initially in development at Merck for Parkinson's disease. Increasing evidence in the literature points to NMDA receptors as promising targets in treating depression, including well-known studies with ketamine, an NMDA antagonist.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.